ArticleBritish journal of cancer2026
Novel transcription factor zinc finger 514 suppresses lung adenocarcinoma progression and enhances cisplatin sensitivity via transcriptional repression of COL1A1.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe extracellular matrix (ECM) plays a pivotal role in lung adenocarcinoma (LUAD) progression and chemoresistance, yet its regulatory mechanisms remain incompletely understood. Here, we identify ZNF514 as a novel tumour suppressor that critically governs ECM remodelling.
methodsTo elucidate the role of ZNF514 in LUAD, we employed a multi-platform approach integrating LUAD organoids, tumour specimens, xenograft mouse models, and cancer cell lines. Transcriptomic profiling was performed to assess ZNF514 expression and its clinical prognostic relevance. Mechanistically, chromatin immunoprecipitation (ChIP) assay, dual-luciferase reporter assay and pathway enrichment analyses identified ZNF514 as a transcriptional repressor of collagen-encoding genes.
resultsAnalyses of LUAD clinical tissues, patient-derived organoids, and The Cancer Genome Atlas (TCGA) datasets revealed a significant downregulation of ZNF514, which correlated with poor prognosis. Functionally, ZNF514 overexpression suppressed organoid formation, subcutaneous tumour growth, and cellular migration and invasion, while enhancing cisplatin (DDP) sensitivity. Mechanistically, RNA sequencing, ChIP assay and dual-luciferase reporter assays identified COL1A1 as a direct transcriptional target of ZNF514. ZNF514 directly binds to the COL1A1 promoter and represses its transcription, thereby contributing, at least in part, to altered extracellular matrix (ECM) remodelling and attenuation of COL1A1-associated epithelial-mesenchymal transition (EMT) in LUAD models.
conclusionsTogether, these findings identify ZNF514 as a tumour-suppressive transcription factor that inhibits LUAD proliferation, invasion, and migration and enhances cisplatin sensitivity, at least in part, through transcriptional repression of COL1A1 and modulation of ECM remodelling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.